Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Closed to Accrual

As of 5pm EDT 1 September 2010, REC.2 (ECOG E2805) -- ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma -- was closed to further accrual. This trial met its accrual goal with Canadian sites contributing 148 patients (7.7%) in total.

It is expected that all Canadian patients will have completed protocol therapy by September 2011.

Thanks to everyone who helped with this trial!